Last Price Today's Change   Day's Range   Trading Volume
27.10   -0.41 (1.49%)  26.74 - 28.14  134,419


Avg Volume (4 weeks):85,108
4 Weeks Range:26.74 - 30.00
4 Weeks Price Volatility (%):
52 Weeks Range:19.53 - 31.235
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European Commission for adults with EPP. It has operations in Europe, the United States and Singapore. SCENESSE acts by increasing the levels of melanin in the skin and shields against UV radiation (UVR) and sunlight. SCENESSE is delivered via a subcutaneous dissolving implant.

  Be the first to like this.
VSOLAR Sailang Margin All In Potential 20 baggers
11/06/2019 2:49 PM
kryptonite wah sifu, you really know how to lepak around hor, kikikikikiki
11/06/2019 11:58 PM

I3 Messenger
Individual or Group chat with anyone on I3investor

668  879  643  1803 

Top 10 Active Counters
 88E 0.044+0.003 
 CLE 0.003-0.006 
 ROG 0.01+0.001 
 LPD 0.018+0.003 
 FNT 0.018+0.002 
 PAB 0.04-0.009 
 PKD 0.054+0.017 
 CLZ 0.001-0.001 
 CRO 0.069+0.008 
 AUZ 0.019-0.001